Renal Sympathetic Denervation and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors (Re-Shape)
Primary Purpose
Hypertension, Resistant to Conventional Therapy
Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Renal sympathetic denervation
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension, Resistant to Conventional Therapy focused on measuring Renal denervation, Resistant Hypertension, Cardiovascular disease, Diabetes, Quality of LIfe
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 Years.
- Resistant hypertension, as defined in the 2007 ESH-ESC guidelines and confirmed by ambulatory or home blood pressure measurements. (Here office BP > 140/90 mmHg on 4 or more antihypertensive drugs in adequate dosages (including one diuretic) or certified drug intolerance).
- No known secondary reason for hypertension
- Negative pregnancy test (preferably blood hCG) for female patients of childbearing potential
- Estimated GFR (glomerular filtration rate) > 45 mL/min/1.73m².
- Willing and able to comply with follow-up requirements
- Signed informed consent
Exclusion Criteria:
- Type 1 and type 2 diabetes
- Pregnancy
- Allergy to the contrast medium used during RDN and Iohexol clearance.
- Age > 68 years
- Hemodynamically significant heart valve disease
- Pacemaker or ICD
- Medication that may interfere with the procedure (Anticoagulation, Platelet inhibitors, Steroids), if they cannot be temporarily reduced or stopped.
- Cancer
- Patients with transplanted kidneys
- Reno vascular conditions like diameter < 4mm, renal artery stenosis or significant atherosclerosis, previous renal artery stenting
Sites / Locations
- University Hospital of North Norway
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Renal sympathetic denervation
Arm Description
Patients with treatment resistant hypertension
Outcomes
Primary Outcome Measures
Change in blood pressure
Change in blood pressure from baseline to six months after the intervention
Change in blood pressure
Change in blood pressure from baseline to two years after the intervention
Secondary Outcome Measures
Change in quality of Life
The international questionnaires SF-36 and 15-D, with some additional specific questions previously used in international studies will be used for evaluation of RDN effect on symptoms and QOL.
Changes in glucose production and insulin sensitivity
Glucose metabolism will be assessed with oral glucose tolerance test and 2-step euglycemic, hyperinsulinaemic clamp with tracer technique (6,6-2H2-glucose + HOTGINF / measurement of tracer-to-tracee ratio with mass spectrometry): Assessment of endogenous glucose production at fasting condition, at insulin levels around 30 mU/ml (hepatic insulin sensitivity), and at insulin levels of 65-68 mU/ml, imitating the postprandial state (peripheral insulin resistance). Assessment of glucose uptake at these conditions (insulin sensitivity).
Change in quality of Life
The international questionnaires SF-36 and 15-D, with some additional specific questions previously used in international studies will be used for evaluation of RDN effect on symptoms and QOL.
Changes in glucose production and insulin sensitivity
Glucose metabolism will be assessed with oral glucose tolerance test and 2-step euglycemic, hyperinsulinaemic clamp with tracer technique (6,6-2H2-glucose + HOTGINF / measurement of tracer-to-tracee ratio with mass spectrometry): Assessment of endogenous glucose production at fasting condition, at insulin levels around 30 mU/ml (hepatic insulin sensitivity), and at insulin levels of 65-68 mU/ml, imitating the postprandial state (peripheral insulin resistance). Assessment of glucose uptake at these conditions (insulin sensitivity).
Effect of RDN on subclinical organ injury: Myocardium
Long standing hypertension leads to sub-clinical organ damage:
Myocardial and vascular remodeling measured with echo cardiography. Wall stiffness, left ventricular function, hypertrophy and mass.
Effect of RDN on subclinical organ injury: Myocardium
Long standing hypertension leads to sub-clinical organ damage:
Myocardial and vascular remodeling measured with echo cardiography. Wall stiffness, left ventricular function, hypertrophy and mass.
Effect of RDN on subclinical organ injury: Retinal vessels
Long standing hypertension leads to sub-clinical organ damage:
Changes in the microcirculatory vasculature detectable as early changes in retinal vascular caliber or presence of hypertensive retinopathy. High resolution photography (Carl Zeiss Meditec.) and optic coherence tomography of the retina give a direct view to microcirculation. Analyzes will be performed using computer assisted morphometry (IVAN/Retinal Analysis software. Fundus Reading center, University of Wisconsin, Madison USA).
Effect of RDN on subclinical organ injury: Retinal vessels
Long standing hypertension leads to sub-clinical organ damage:
Changes in the microcirculatory vasculature detectable as early changes in retinal vascular caliber or presence of hypertensive retinopathy. High resolution photography (Carl Zeiss Meditec.) and optic coherence tomography of the retina give a direct view to microcirculation. Analyzes will be performed using computer assisted morphometry (IVAN/Retinal Analysis software. Fundus Reading center, University of Wisconsin, Madison USA).
Effect of RDN on subclinical organ injury: Kidneys
Long standing hypertension leads to sub-clinical organ damage:
Renal dysfunction. We will measure serum creatinine, cystatin C, GFR (iohexol clearance), albumine/creatinine ratio and N-Acetyl-ß-glucosaminidase (NAG) in morning urine (two different days) before and after RDN. NAG excretion is a sign of tubular injury.
Effect of RDN on subclinical organ injury: Kidneys
Long standing hypertension leads to sub-clinical organ damage:
Renal dysfunction. We will measure serum creatinine, cystatin C, GFR (iohexol clearance), albumine/creatinine ratio and N-Acetyl-ß-glucosaminidase (NAG) in morning urine (two different days) before and after RDN. NAG excretion is a sign of tubular injury.
Effect of RDN on subclinical organ injury: Endothelial function
Long standing hypertension leads to sub-clinical organ damage:
Impaired endothelial function; assessed with plethysmography under reactive hyperemia + markers of endothelial dysfunction; Peripheral vasodilator function is measured by digital pulse amplitude tonometry using EndoPAT 2000 (Itamar Medical Ltd., Caesarea, Israel). Reactive hyperemia is produced by applying a blood pressure cuff for 5 min at a pressure of 60 mmHg higher than the systolic pressure on the upper part of the arm.
Effect of RDN on subclinical organ injury: Endothelial function
Long standing hypertension leads to sub-clinical organ damage:
Impaired endothelial function; assessed with plethysmography under reactive hyperemia + markers of endothelial dysfunction; Peripheral vasodilator function is measured by digital pulse amplitude tonometry using EndoPAT 2000 (Itamar Medical Ltd., Caesarea, Israel). Reactive hyperemia is produced by applying a blood pressure cuff for 5 min at a pressure of 60 mmHg higher than the systolic pressure on the upper part of the arm.
Effect of RDN on subclinical organ injury: Impedance cardiography
Increased central blood pressure measured in ascending aorta, in addition to "augmentation index" (peak aortic pressure increase/pulse pressure) as a measure of vessel compliance, are independent predictors for hypertensive organ injury (brain, heart, kidneys). Aortic wall-stiffness (compliance) and pulse wave reflection are important determinants for central blood pressure and are among the parameters we indirectly will get from impedance cardiography (Hotman System, HEMO SAPIENS INC, Bucharest, Romania)
Effect of RDN on subclinical organ injury: Impedance cardiography
Increased central blood pressure measured in ascending aorta, in addition to "augmentation index" (peak aortic pressure increase/pulse pressure) as a measure of vessel compliance, are independent predictors for hypertensive organ injury (brain, heart, kidneys). Aortic wall-stiffness (compliance) and pulse wave reflection are important determinants for central blood pressure and are among the parameters we indirectly will get from impedance cardiography (Hotman System, HEMO SAPIENS INC, Bucharest, Romania)
Full Information
NCT ID
NCT01630928
First Posted
June 26, 2012
Last Updated
May 13, 2016
Sponsor
University Hospital of North Norway
Collaborators
University of Tromso, The Royal Norwegian Ministry of Health, Odd Berg Medical research Foundation
1. Study Identification
Unique Protocol Identification Number
NCT01630928
Brief Title
Renal Sympathetic Denervation and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors
Acronym
Re-Shape
Official Title
Renal Sympathetic Denervation for Treatment Resistant Hypertension and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors (The Re-Shape CV-Risk Study)
Study Type
Interventional
2. Study Status
Record Verification Date
May 2016
Overall Recruitment Status
Completed
Study Start Date
March 2013 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital of North Norway
Collaborators
University of Tromso, The Royal Norwegian Ministry of Health, Odd Berg Medical research Foundation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The Re-Shape CV-Risk Study is a clinical study where renal adrenergic denervation (RDN) is done in high risk patients with treatment-resistant hypertension. RDN is a mini-invasive, percutaneous technique where an ablation catheter is inserted through a femoral artery into the renal arteries, for destruction of the adrenergic nerve bundles in the artery adventitia by means of radio-frequency ablation. RDN leads to sympathetic denervation of the kidneys, which in the "Symplicity trials" led to an impressive reduction of blood pressure (- 33 /-11 mmHg). In a pilot study, where 40 % of the patients had diabetes, RDN seemed to have beneficial effects not only on blood pressure, but also on insulin sensitivity and hyperinsulinaemia.
The investigators aim to introduce RDN as a clinical study where blood pressure reduction and methodical, technical aspects will be evaluated, but more importantly, also additional effects of RDN on sub-clinical organ damage (endothelial function, vascular stiffness, fundus-, heart-, kidney injury), quality of life, arrhythmia, and glucose metabolism. The investigators hypothesis is that RDN will have positive effect on glucose metabolism, QOL and sub-clinical organ damage.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Resistant to Conventional Therapy
Keywords
Renal denervation, Resistant Hypertension, Cardiovascular disease, Diabetes, Quality of LIfe
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Renal sympathetic denervation
Arm Type
Experimental
Arm Description
Patients with treatment resistant hypertension
Intervention Type
Procedure
Intervention Name(s)
Renal sympathetic denervation
Other Intervention Name(s)
Symplicity Catheter (Medtronic)
Intervention Description
This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
Primary Outcome Measure Information:
Title
Change in blood pressure
Description
Change in blood pressure from baseline to six months after the intervention
Time Frame
from baseline to six months
Title
Change in blood pressure
Description
Change in blood pressure from baseline to two years after the intervention
Time Frame
from baseline to two years
Secondary Outcome Measure Information:
Title
Change in quality of Life
Description
The international questionnaires SF-36 and 15-D, with some additional specific questions previously used in international studies will be used for evaluation of RDN effect on symptoms and QOL.
Time Frame
From baseline to six months
Title
Changes in glucose production and insulin sensitivity
Description
Glucose metabolism will be assessed with oral glucose tolerance test and 2-step euglycemic, hyperinsulinaemic clamp with tracer technique (6,6-2H2-glucose + HOTGINF / measurement of tracer-to-tracee ratio with mass spectrometry): Assessment of endogenous glucose production at fasting condition, at insulin levels around 30 mU/ml (hepatic insulin sensitivity), and at insulin levels of 65-68 mU/ml, imitating the postprandial state (peripheral insulin resistance). Assessment of glucose uptake at these conditions (insulin sensitivity).
Time Frame
from baseline to six months
Title
Change in quality of Life
Description
The international questionnaires SF-36 and 15-D, with some additional specific questions previously used in international studies will be used for evaluation of RDN effect on symptoms and QOL.
Time Frame
From baseline to two years
Title
Changes in glucose production and insulin sensitivity
Description
Glucose metabolism will be assessed with oral glucose tolerance test and 2-step euglycemic, hyperinsulinaemic clamp with tracer technique (6,6-2H2-glucose + HOTGINF / measurement of tracer-to-tracee ratio with mass spectrometry): Assessment of endogenous glucose production at fasting condition, at insulin levels around 30 mU/ml (hepatic insulin sensitivity), and at insulin levels of 65-68 mU/ml, imitating the postprandial state (peripheral insulin resistance). Assessment of glucose uptake at these conditions (insulin sensitivity).
Time Frame
from baseline to two years
Title
Effect of RDN on subclinical organ injury: Myocardium
Description
Long standing hypertension leads to sub-clinical organ damage:
Myocardial and vascular remodeling measured with echo cardiography. Wall stiffness, left ventricular function, hypertrophy and mass.
Time Frame
from baseline to six months
Title
Effect of RDN on subclinical organ injury: Myocardium
Description
Long standing hypertension leads to sub-clinical organ damage:
Myocardial and vascular remodeling measured with echo cardiography. Wall stiffness, left ventricular function, hypertrophy and mass.
Time Frame
from baseline to two years
Title
Effect of RDN on subclinical organ injury: Retinal vessels
Description
Long standing hypertension leads to sub-clinical organ damage:
Changes in the microcirculatory vasculature detectable as early changes in retinal vascular caliber or presence of hypertensive retinopathy. High resolution photography (Carl Zeiss Meditec.) and optic coherence tomography of the retina give a direct view to microcirculation. Analyzes will be performed using computer assisted morphometry (IVAN/Retinal Analysis software. Fundus Reading center, University of Wisconsin, Madison USA).
Time Frame
from baseline to six months
Title
Effect of RDN on subclinical organ injury: Retinal vessels
Description
Long standing hypertension leads to sub-clinical organ damage:
Changes in the microcirculatory vasculature detectable as early changes in retinal vascular caliber or presence of hypertensive retinopathy. High resolution photography (Carl Zeiss Meditec.) and optic coherence tomography of the retina give a direct view to microcirculation. Analyzes will be performed using computer assisted morphometry (IVAN/Retinal Analysis software. Fundus Reading center, University of Wisconsin, Madison USA).
Time Frame
from baseline to two years
Title
Effect of RDN on subclinical organ injury: Kidneys
Description
Long standing hypertension leads to sub-clinical organ damage:
Renal dysfunction. We will measure serum creatinine, cystatin C, GFR (iohexol clearance), albumine/creatinine ratio and N-Acetyl-ß-glucosaminidase (NAG) in morning urine (two different days) before and after RDN. NAG excretion is a sign of tubular injury.
Time Frame
from baseline to six months
Title
Effect of RDN on subclinical organ injury: Kidneys
Description
Long standing hypertension leads to sub-clinical organ damage:
Renal dysfunction. We will measure serum creatinine, cystatin C, GFR (iohexol clearance), albumine/creatinine ratio and N-Acetyl-ß-glucosaminidase (NAG) in morning urine (two different days) before and after RDN. NAG excretion is a sign of tubular injury.
Time Frame
from baseline to two years
Title
Effect of RDN on subclinical organ injury: Endothelial function
Description
Long standing hypertension leads to sub-clinical organ damage:
Impaired endothelial function; assessed with plethysmography under reactive hyperemia + markers of endothelial dysfunction; Peripheral vasodilator function is measured by digital pulse amplitude tonometry using EndoPAT 2000 (Itamar Medical Ltd., Caesarea, Israel). Reactive hyperemia is produced by applying a blood pressure cuff for 5 min at a pressure of 60 mmHg higher than the systolic pressure on the upper part of the arm.
Time Frame
from baseline to six months
Title
Effect of RDN on subclinical organ injury: Endothelial function
Description
Long standing hypertension leads to sub-clinical organ damage:
Impaired endothelial function; assessed with plethysmography under reactive hyperemia + markers of endothelial dysfunction; Peripheral vasodilator function is measured by digital pulse amplitude tonometry using EndoPAT 2000 (Itamar Medical Ltd., Caesarea, Israel). Reactive hyperemia is produced by applying a blood pressure cuff for 5 min at a pressure of 60 mmHg higher than the systolic pressure on the upper part of the arm.
Time Frame
from baseline to two years
Title
Effect of RDN on subclinical organ injury: Impedance cardiography
Description
Increased central blood pressure measured in ascending aorta, in addition to "augmentation index" (peak aortic pressure increase/pulse pressure) as a measure of vessel compliance, are independent predictors for hypertensive organ injury (brain, heart, kidneys). Aortic wall-stiffness (compliance) and pulse wave reflection are important determinants for central blood pressure and are among the parameters we indirectly will get from impedance cardiography (Hotman System, HEMO SAPIENS INC, Bucharest, Romania)
Time Frame
from baseline to two years
Title
Effect of RDN on subclinical organ injury: Impedance cardiography
Description
Increased central blood pressure measured in ascending aorta, in addition to "augmentation index" (peak aortic pressure increase/pulse pressure) as a measure of vessel compliance, are independent predictors for hypertensive organ injury (brain, heart, kidneys). Aortic wall-stiffness (compliance) and pulse wave reflection are important determinants for central blood pressure and are among the parameters we indirectly will get from impedance cardiography (Hotman System, HEMO SAPIENS INC, Bucharest, Romania)
Time Frame
from baseline to six months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 Years.
Resistant hypertension, as defined in the 2007 ESH-ESC guidelines and confirmed by ambulatory or home blood pressure measurements. (Here office BP > 140/90 mmHg on 4 or more antihypertensive drugs in adequate dosages (including one diuretic) or certified drug intolerance).
No known secondary reason for hypertension
Negative pregnancy test (preferably blood hCG) for female patients of childbearing potential
Estimated GFR (glomerular filtration rate) > 45 mL/min/1.73m².
Willing and able to comply with follow-up requirements
Signed informed consent
Exclusion Criteria:
Type 1 and type 2 diabetes
Pregnancy
Allergy to the contrast medium used during RDN and Iohexol clearance.
Age > 68 years
Hemodynamically significant heart valve disease
Pacemaker or ICD
Medication that may interfere with the procedure (Anticoagulation, Platelet inhibitors, Steroids), if they cannot be temporarily reduced or stopped.
Cancer
Patients with transplanted kidneys
Reno vascular conditions like diameter < 4mm, renal artery stenosis or significant atherosclerosis, previous renal artery stenting
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Terje K. Steigen, MD, PhD
Organizational Affiliation
Dept. of Cardiology, University Hospital of North Norway and University of Tromsø, Norway
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ingrid Toft, MD, PhD
Organizational Affiliation
Dept. of Nephrology, University Hospital of North Norway and University of Tromsø
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Marit D Solbu, MD, PhD
Organizational Affiliation
Dept of Nephrology, University Hospital of North Norway and University of Tromsø
Official's Role
Study Director
Facility Information:
Facility Name
University Hospital of North Norway
City
Tromsø
ZIP/Postal Code
N-9038
Country
Norway
12. IPD Sharing Statement
Citations:
PubMed Identifier
35686551
Citation
Hanssen TA, Subbotina A, Miroslawska A, Solbu MD, Steigen TK. Quality of life following renal sympathetic denervation in treatment-resistant hypertensive patients: a two-year follow-up study. Scand Cardiovasc J. 2022 Dec;56(1):174-179. doi: 10.1080/14017431.2022.2084562.
Results Reference
derived
PubMed Identifier
27246911
Citation
Miroslawska AK, Gjessing PF, Solbu MD, Fuskevag OM, Jenssen TG, Steigen TK. Renal Denervation for Resistant Hypertension Fails to Improve Insulin Resistance as Assessed by Hyperinsulinemic-Euglycemic Step Clamp. Diabetes. 2016 Aug;65(8):2164-8. doi: 10.2337/db16-0205. Epub 2016 May 31.
Results Reference
derived
Learn more about this trial
Renal Sympathetic Denervation and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors
We'll reach out to this number within 24 hrs